Orasure Technologies Inc. (OSUR)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1116463 · fiscal year ends in Dec
Closing price $3.94 on 30 Oct 2026; 52-week range $2.11 to $4.50.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $112.4M
- Revenue growth
- -18.9%
- Net income, last twelve months
- -$49.1M
- Earnings per share
- -$0.69
- Gross margin
- 42.6%
- Operating margin
- -48.1%
- Net margin
- -43.7%
- Free cash flow
- -$48.1M
- Return on equity
- -15.5%
- Market value
- $271.7M
- Cash
- $160.6M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 69.0M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $115.0M | -$72.0M | -$68.7M | -$0.94 | -$53.2M | 10-K filed 9 Mar 2026 |
| FY2024 | 31 Dec 2024 | $185.8M | -$28.3M | -$19.5M | -$0.26 | $23.6M | 10-K filed 7 Mar 2025 |
| FY2023 | 31 Dec 2023 | $405.5M | $32.7M | $53.7M | $0.72 | $135.8M | 10-K filed 11 Mar 2024 |
| FY2022 | 31 Dec 2022 | $387.5M | -$22.2M | -$17.1M | -$0.24 | -$54.0M | 10-K filed 3 Mar 2023 |
| FY2021 | 31 Dec 2021 | $233.7M | -$10.2M | -$23.0M | -$0.32 | -$57.3M | 10-K filed 1 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $30.6M | $6.2M | $0.09 |
| Q1 FY2026 | 31 Mar 2026 | $27.9M | -$22.4M | -$0.32 |
| Q4 FY2025 | 31 Dec 2025 | $26.8M | -$19.3M | -$0.27 |
| Q3 FY2025 | 30 Sep 2025 | $27.1M | -$13.7M | -$0.19 |
| Q2 FY2025 | 30 Jun 2025 | $31.2M | -$19.7M | -$0.26 |
| Q1 FY2025 | 31 Mar 2025 | $29.9M | -$16.0M | -$0.21 |
| Q4 FY2024 | 31 Dec 2024 | $37.4M | -$10.8M | -$0.14 |
| Q3 FY2024 | 30 Sep 2024 | $39.9M | -$4.5M | -$0.06 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Products and services | $109.1M | 94.8% |
| Other | $6.0M | 5.2% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $78.3M | 68.0% |
| Africa | $24.0M | 20.9% |
| Europe | $7.4M | 6.4% |
| Other regions | $5.4M | 4.7% |
Company events
The newest 8-K filings of 279 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 11 Jun 2026 | 8-K | Other events | 8.01 |
| 3 Jun 2026 | 8-K | Leadership change, Shareholder vote, Bylaws or fiscal year change | 5.02, 5.03, 5.07, 9.01 |
| 6 May 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 17 Apr 2026 | 8-K | Leadership change, Material agreement, Investor update | 1.01, 5.02, 7.01, 9.01 |
| 30 Mar 2026 | 8-K | Investor update | 7.01, 9.01 |
| 5 Mar 2026 | 8-K | Leadership change | 5.02 |
| 25 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 5 Jan 2026 | 8-K | Investor update, Other events | 7.01, 8.01, 9.01 |
| 1 Dec 2025 | 8-K | Other events | 8.01 |
| 5 Nov 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 28 Oct 2025 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 602 held.
| Filed | Form | Period |
|---|---|---|
| 7 Aug 2026 | S-8 | – |
| 7 Aug 2026 | 10-Q | 30 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 11 Jun 2026 | 8-K | 11 Jun 2026 |
| 3 Jun 2026 | 8-K | 3 Jun 2026 |
| 8 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEF 14A | 31 Dec 2025 |
| 20 Apr 2026 | PRE 14A | 31 Dec 2025 |
| 17 Apr 2026 | DEFA14A | – |
| 17 Apr 2026 | DEFA14A | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 29 Sep 2026 | Boyd Steven Kyle, Director | Took pay in stock | 4,797 | $3.88 | $18.6K | – | 1 Oct 2026 |
| 26 Jun 2026 | Boyd Steven Kyle, Director | Took pay in stock | 3,666 | $4.43 | $16.3K | – | 30 Jun 2026 |
| 14 May 2026 | Boyd Steven Kyle, Director | Purchase | 25,000 | $2.99 | $74.8K | 113,462 | 14 May 2026 |
| 13 May 2026 | Boyd Steven Kyle, Director | Purchase | 25,000 | $3.02 | $75.5K | 88,462 | 14 May 2026 |
| 12 May 2026 | Boyd Steven Kyle, Director | Purchase | 25,000 | $2.98 | $74.5K | 63,462 | 14 May 2026 |
| 26 Mar 2026 | Boyd Steven Kyle, Director | Took pay in stock | 5,246 | $3.10 | $16.2K | – | 30 Mar 2026 |
| 20 Mar 2026 | Mcgrath Kenneth J, Chief Financial Officer | Purchase | 32,300 | $2.93 | $94.6K | 589,562 | 23 Mar 2026 |
| 20 Mar 2026 | Eglinton Manner Carrie, President & CEO | Purchase | 32,300 | $2.93 | $94.6K | 2,190,874 | 23 Mar 2026 |
| 13 Mar 2026 | Mcgrath Kenneth J, Chief Financial Officer | Purchase | 22,021 | $3.00 | $66.0K | 557,262 | 16 Mar 2026 |
| 13 Mar 2026 | Eglinton Manner Carrie, President & CEO | Purchase | 22,022 | $3.00 | $66.0K | 2,158,574 | 16 Mar 2026 |
| 17 Dec 2025 | Kenny John P., Director | Took pay in stock | 10,286 | $2.46 | $25.3K | – | 19 Dec 2025 |
| 28 Nov 2025 | Gagliano Nancy J, Director | Purchase | 2,100 | $2.37 | $5.0K | 160,254 | 2 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 4 Dec 2025 | Mara Aspinall, Board | 89,716 | $225.0K | 4 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 30 Oct 2026 | Vanguard Capital Management | 13G amended | 4.82% | 3.3M |
| 17 Sep 2026 | Islet Management, LP | 13D | 5.7% | 3.9M |
| 12 Aug 2026 | Gagnon Securities LLC | 13G | 5.8% | 8.9M |
| 31 Jul 2026 | PRIVATE MANAGEMENT GROUP INC | 13G amended | 5.5% | 3.8M |
| 30 Apr 2026 | Vanguard Capital Management | 13G | 5.04% | 3.5M |
| 20 Apr 2026 | Altai Capital Management, L.P. | 13D amended | 5.2% | 3.6M |
| 8 Apr 2026 | Gagnon Securities LLC | 13G | 5.4% | 3.8M |
| 27 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 17 Mar 2026 | Altai Capital Management, L.P. | 13D amended | 5.2% | 3.6M |
| 12 Feb 2026 | Gagnon Securities LLC | 13G amended | 4.9% | 3.6M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 2.7M | -6.83% | 5.73 |
| 30 Sep 2026 | 2.9M | -7.61% | 4.52 |
| 15 Sep 2026 | 3.2M | +1.35% | 5.98 |
| 31 Aug 2026 | 3.1M | -0.43% | 8.22 |
| 14 Aug 2026 | 3.1M | +5.96% | 6.09 |
| 31 Jul 2026 | 3.0M | -9.14% | 8.14 |
| 15 Jul 2026 | 3.3M | +9.83% | 8.97 |
| 30 Jun 2026 | 3.0M | -3.41% | 3.98 |
Funds that hold it
From each fund's latest Form 13F.
166 funds held it at 30 Jun 2026: 62 added and 50 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 6,256,762 | $27.9M | -259,454 |
| Neuberger Berman Group LLC | 4,685,432 | $20.9M | +323,531 |
| Private Management Group Inc. | 3,797,682 | $16.9M | -1,624,447 |
| Altai Capital Management, L.P. | 3,613,836 | $16.1M | 0 |
| Vanguard Capital Management LLC | 3,018,907 | $13.5M | -11,981 |
| Systematic Financial Management LP | 2,857,974 | $12.7M | +377,491 |
| Dimensional Fund Advisors LP | 2,340,901 | $10.4M | -479,929 |
| First Eagle Investment Management, LLC | 2,125,500 | $9.5M | – |
| Acadian Asset Management LLC | 2,022,119 | $9.0M | 0 |
| Renaissance Technologies LLC | 2,014,903 | $9.0M | -68,400 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B